TRINETRA › Sectors › Healthcare
Hikal Limited (HIKAL) — share price, P/E and fundamentals
Hikal Limited (NSE: HIKAL) closed at ₹211.58 on 30 Oct 2026, -11.8% over one year, against a 52-week range of ₹146.25 – ₹261.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 6 Aug 2026) it reported revenue of ₹403 cr and a net loss of ₹7 cr, a -1.8% net margin; revenue grew 5.9% year on year.
No trailing P/E is published: trailing twelve-month earnings are negative (-34 cr), so a P/E has no meaning — a loss-making business is not 'cheap' at a negative multiple. Judge it on revenue growth, cash burn and funding instead.
From the balance sheet dated 31 Mar 2026: return on equity -2.5%, ROCE 1.2%, debt-to-equity 0.57, Piotroski F-score 6 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 3% of 64 sector peers; PBT margin higher than 3% of 64 sector peers; ROE higher than 4% of 64 sector peers.
Key figures
| Last close | ₹211.58 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -1.2% / +16.8% / -11.8% |
| 52-week low – high | ₹146.25 – ₹261.00 |
| Market capitalisation | ₹2,613 cr |
| Price / book | 2.18 |
| EV / EBITDA | 19.4 |
| TTM EPS | ₹-2.74 |
| TTM net profit | ₹-34 cr |
| Quarter revenue | ₹403 cr |
| Quarter net loss | ₹7 cr |
| Net margin | -1.8% |
| Revenue growth (YoY) | +5.9% |
| Profit growth (YoY) | +67.4% |
| Return on equity | -2.5% |
| ROCE | 1.2% |
| Debt / equity | 0.57 |
| Current ratio | 1.30 |
| Free cash flow | ₹154 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹7.4 cr |
Against Healthcare peers
| Metric | HIKAL | Peer median | Percentile |
|---|---|---|---|
| Net margin | -1.84 | 12.89 | 3 |
| PBT margin | -2.46 | 17.68 | 3 |
| ROE | -2.47 | 13.87 | 4 |
| ROCE | 1.19 | 17.26 | 5 |
| Debt / equity | 0.57 | 0.11 | 90 |
| P/B | 2.18 | 6.02 | 7 |
| EV/EBITDA | 19.41 | 22.34 | 38 |
Questions
What were Hikal Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Hikal Limited reported revenue of ₹403 cr and a net loss of ₹7 cr (consolidated), filed with the exchange on 6 Aug 2026.
What is Hikal Limited's ROE?
Return on equity is -2.5% based on the balance sheet dated 31 Mar 2026.
Does Hikal Limited have debt?
Debt-to-equity is 0.57 on the balance sheet dated 31 Mar 2026.
What is HIKAL's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, HIKAL traded between ₹146.25 and ₹261.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.